Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$18.10 USD
+0.12 (0.67%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $18.28 +0.18 (0.99%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JSPR 18.10 +0.12(0.67%)
Will JSPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JSPR
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
JSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength
Other News for JSPR
Jasper Therapeutics price target lowered by $2 at RBC Capital, here's why
Oppenheimer Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)
RBC Capital Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
Buy Rating Reaffirmed for Jasper Therapeutics on Strong Clinical Performance and Market Potential
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q2 2024